SUPPLEMENTARY ONLINE REPOSITORY ATF6a regulates airway hyperreactivity, smooth muscle proliferation, and contractility Hirotoshi Unno MD PhD^a, Marina Miller, MD, PhD^a, Peter Rosenthal, BS^a, Andrew Beppu, BS^a, Sudipta Das, PhD^a, David H. Broide, MB. Ch.B.^a ^aDepartment of Medicine, University of California San Diego, La Jolla, California Corresponding author: David Broide, MB ChB., University of California San Diego 9500 Gilman Drive, MC 0635 La Jolla, CA 92093-0635 Fax: (858) 534-2110 Email: dbroide@ucsd.edu

24 SUPPLEMENTARY METHODS

25 Mouse model of house dust mite (HDM) induced asthma

ATF6α deficient mice (kindly provided by Dr Mori)^{E1} on a C57Bl6 background and WT control 26 27 C57Bl6 mice aged approximately 12 weeks were either challenged with HDM (Greer)(HDM 28 group)(n=8 mice/ group), or not challenged with HDM (no HDM group) (n=8 mice/ group) as previously described^{E2}. The HDM used in this study contains 1,145 µg Der p 1 per 25 ml vial 29 (Greer product certification of analysis sheet). In brief in the HDM group, ATF6a deficient or 30 31 WT mice were intranasally administered 100 µg HDM in 50 µl PBS on day 0, 7, 14, and 21. On 32 day 24, AHR was measured, mice were sacrificed and bronchoalveolar lavage (BAL) fluid and 33 lungs collected to quantitate levels of airway inflammation and airway remodeling as described 34 below. All experimental mouse protocols were approved by the UCSD Institutional Animal Care 35 and Use Committee.

36

37 Measurement of airway hyperresponsiveness

Airway responsiveness to methacholine was assessed in intubated and ventilated mice aged 12 wk (n = 8 mice/group) (flexiVent ventilator; Scireq) using Scireq software on day 24 of the HDM mouse protocol. Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) i.p. and exposed to nebulized PBS and methacholine (0, 3, 24, and 48 mg/ml) as previously described^{E3}. The following ventilator settings were used: tidal volume (10 ml/kg), frequency (150/min), and positive end-expiratory pressure (3 cmH₂O).

44

45

47 Lung processing

Lungs were processed for immunohistology (paraffin-embedded lung sections) as previously described in this laboratory^{E3,E4}. In brief, lungs were equivalently inflated with an intratracheal injection of the same volume of 4% paraformaldehyde solution (Sigma Chemicals, St. Louis, MO) to preserve the pulmonary architecture.

52

53 Assessment of thickness of airway smooth muscle layer

54 The thickness of the airway smooth muscle layer was measured by α -smooth actin immunohistochemistry as previously described^{E3,E4}. Lung sections were immunostained with an 55 56 anti-mouse a-smooth muscle actin Ab to detect peribronchial smooth muscle. The area of 57 peribronchial a-smooth muscle actin staining in paraffin-embedded lungs was outlined and quantified under a light microscope (Leica DMLS, Leica Micro systems) attached to image 58 analysis system (image-Pro plus, Media Cybernetics, Bethesda MD) as previously described^{E3,E4}. 59 60 Results are expressed as the area of peribronchial α -smooth actin staining per micrometer length 61 of basement membrane of bronchioles 150-200 µm internal diameter.

62

63 Assessment of peribronchial fibrosis

64 The area of peribronchial trichrome staining in paraffin-embedded lungs was outlined and 65 quantified under a light microscope attached to image analysis system as previously 66 described^{E3,E4}. Results are expressed as the area of peribronchial trichrome staining per 67 micrometer length of basement membrane of bronchioles 150-200 μm internal diameter.

68

70 Airway mucus expression.

To quantitate the level of mucus expression in the airway, the number of periodic acid-Schiff
(PAS) ⁺ cells in similar sized individual bronchioles was counted as previously described^{E3,E4}.
Results are expressed as the number of PAS⁺ cells per bronchiole.

74

75 Assessment of airway inflammation

BAL cell counts. BAL fluid was collected by lavaging the lung with 1 ml PBS via a tracheal
 catheter as previously described^{E3,E4}. BAL total and differential cell counts were quantified in
 Wright Giemsa stained slides.

79

80 Peribronchial lung eosinophils, neutrophils, macrophages and lymphocytes.

Levels of lung eosinophils, neutrophils, CD4+ lymphocytes, and F4/80 positive macrophages 81 82 were quantitated in the peribronchial space in lung sections processed for immunohistochemistry 83 using an anti-mouse MBP Ab (rabbit polyclonal Ab kindly provided by James Lee PhD, Mayo Clinic, Scottsdale, Arizona), an anti-mouse neutrophil elastase Ab (rat monoclonal Ab SC-84 71674, Santa Cruz, Dallas, Tx), an anti-mouse CD4 Ab (rat monoclonal Ab, GTX85525, 85 86 GeneTex), and an anti-mouse F4/80 Ab (rat monoclonal Ab, SC-52664 Santa Cruz Biotechnology) as previously described^{E3,E4}. The number of individual cells staining positive in 87 88 the peribronchial space was counted using a light microscope. Results are expressed as the 89 number of peribronchial cells staining positive per bronchiole with 150-200 µm of internal 90 diameter. At least five bronchioles were counted in each slide.

91

93 **BAL cytokines**

Levels of IL-5 (R&D Systems, Minneapolis, MN), IL-13 (R&D Systems, Minneapolis, MN),
and TGF-β1 (R&D Systems, Minneapolis, MN) were quantitated by Elisa in BAL fluid obtained
from WT and ATF6α deficient mice.

97

98 Mouse airway smooth muscle (mASM) cell culture

99 Mouse airway smooth muscle was obtained from WT and ATF6a deficient mice as previously described^{E5}. In brief, after mouse sacrifice, the tracheas were excised, cut longitudinally with a 100 101 scalpel to expose the lumen and then transferred to 0.14% Pronase (Roche Applied Science) in 102 Ham's F-12 nutrient medium and incubated at 4°C overnight. The tracheas were then brushed 103 with a cotton swab to remove the remaining adherent epithelial cells, cut into small pieces (~ 30 104 per trachea), and cultured in DMEM/F-12 and 10% FBS for attachment and outgrowth. Four 105 days later, smooth muscle cell outgrowth was apparent, and the cells were left to multiply for 2 more days, after which they were trypsinized and plated into a 175-cm² flask. Confluency was 106 107 reached within about 3-5 days. Experiments were done on the second passage, which was split 108 1:2 from the first passage.

109

110 Human airway smooth muscle (hASM) culture and transfection with ATF6a siRNA

Primary hASM were obtained from Sciencell (Carlsbad, CA)^{E6} .hASM were maintained and cultured in flasks or plates (6, 24 and 96 well) using smooth muscle cell media with smooth muscle growth supplement (ScienCell) and 2% fetal bovine serum. hASM were transfected with either control siRNA or ATF6 α siRNA (100nM) by using transfection reagents siTran1.0 (OROGENE) and Opti-MEM (Thermo Fisher Scientific) according the manufacturer's

116 instructions. The transfected hASM cells were used 48 hrs after the transfection in all 117 experiments. We assessed the efficiency of ATF6 α gene knockdown by qRT-PCR as previously described in this laboratory^{E3,E4}. In brief, total RNA was extracted with RNA-STAT-60 (Tel-118 119 Test) and reverse transcribed with Oligo-dT and SuperScript II kit (Life Technologies). qRT-120 PCR was performed with TaqMan PCR Master Mix and ATF6a primers (all from Life 121 Technology). The relative amounts of transcripts were normalized to those of housekeeping gene 122 (GAPDH) mRNA and compared between control siRNA transfected samples and ATF6a siRNA 123 transfected samples by the $\Delta\Delta$ cycle threshold method as previously described in this laboratory^{E3,E4}. In addition, we quantitated levels of ATF6a protein in hASM cells transfected 124 with either control siRNA or ATF6a siRNA by western blot as previously described in this 125 laboratory^{E4}. In brief, proteins were separated on a SDS/PAGE gel and transferred to a PVDF 126 membrane. Membranes were blocked in 5% (wt/vol) milk in 1x Tris-buffered saline with Tween 127 128 for 1 h and then incubated with primary antibody overnight at 4 °C. The primary antibodies used 129 in this study were mouse monoclonal anti-ATF6a (Abcam), and rabbit monoclonal anti-GAPDH 130 (Genetex).

131

132 **Eotaxin-1**

133 Levels of eotaxin-1 were quantitated by ELISA (R&D Systems, Minneapolis, MN) in the 134 supernatants of hASM transfected with either control siRNA or ATF6 α siRNA and stimulated 135 with IL-13 (100 ng/ml) for 24 hrs.

136

137

139 mASM and hASM contraction assay

140 Either mouse ASM (WT vs ATF6a deficient) or human ASM (control vs ATF6a siRNA 141 transfected) were used in an in vitro smooth muscle gel contraction assay as previously described in this laboratory^{E7}. ASM $(2x10^5 \text{ cells/well})$ were cultured in basal medium without growth 142 143 factors for 24 hours before seeding in collagen gels free of LPS (Advanced BioMatrix, San 144 Diego, Calif). After overnight incubation in collagen gels, ASM cells were cultured in the 145 presence or absence of either diluent (control), methacholine (100 µM) or histamine (200 µM) 146 for varying time periods (0, 15, and 30 min). With agonist-induced ASM contraction, the area of the gel decreases significantly, as described in studies of ASM^{E7}. The area of the gels was 147 148 quantitated by using a Bio-Rad ImageDR transilluminator and Versadoc scanner (Bio-Rad 149 Laboratories, Hercules, Calif) with an accompanying image-capture and analysis program to 150 generate the area in square millimeters. Results are expressed as % contraction, which compares 151 the area of the gel at the time point studied to the area of the gel at baseline (0 min).

152

153 mASM and hASM Proliferation

mASM and hASM proliferation was assessed by BrdU incorporation using a BrdU ELISA (Exalpha Biological). BrdU incorporation in either mouse ASM (WT vs ATF6 α deficient) or human ASM (control vs ATF6 α siRNA transfected) was assessed in ASM (2x10⁴ cells/well) stimulated to proliferate with either 2% FBS (low concentration) or 10% FBS (high concentration), or as a control no FBS in a 96-well microplate. BrdU was added 24hrs after incubating ASM with FBS, and 24hrs later BrdU incorporation was quantitated according to the manufacturer's instructions.

162 mASM and hASM apoptosis.

We used a Caspase-Glo 3/7 apoptosis assay (Promega) to detect caspase-3/7 activity in either mouse ASM (WT vs ATF6a deficient) or human ASM (control vs ATF6a siRNA transfected). In these experiments ASM cells ($2x10^4$ cells/well) were incubated with either 0% FBS, 2% FBS, or 10% FBS in 96-well microplate. The Caspase-Glo 3/7 apoptosis assay utilizes a luminogenic caspase-3/7 substrate, which contains the tetrapeptide sequence DEVD to detect caspase-3/7 activity. Incubation of ASM with 1µM staurosporine a known inducer of apoptosis was used as a positive control. Staurosporine was added 24hrs after incubating ASM with FBS, and 24hrs later caspase-3/7 activity was quantitated according to the manufacturer's instructions. **Statistical analysis** All results are presented as mean + SEM. A statistical software package (Graph Pad Prism, San Diego, CA) was used for the analysis. A t test was used for analysis of two groups. ANOVA analysis was use when more than two groups were compared. P values of < 0.05 were considered statistically significant.

185 SUPPLEMENTARY DISCUSSION

Our in vivo studies used global ATF6 $\alpha^{-/-}$ mice, and thus we are not able to determine whether a 186 deficiency of ATF6a in ASM, or in cell types other than ASM, could have influenced ASM 187 contraction in vivo. It is possible that $ATF6\alpha^{-/-}$ mice have a developmental defect in ASM, 188 although baseline levels of ASM in WT and ATF6 $\alpha^{-/-}$ mice are similar. The increase in ASM 189 mass noted in this study in WT mice with four HDM challenges in vivo over a 3 week period 190 191 may either be due to ASM hypertrophy and/or ASM proliferation and requires further study. 192 Although our in vitro studies demonstrate that ATF6a is required for methacholine or histamine 193 induced ASM proliferation in vitro, further studies are needed to determine the role of ATF6a in 194 ASM proliferation induced by other important stimuli in asthma including leukotrienes and 195 HDM. In this study we only performed experiments on ASM and thus we are not able to state 196 whether ATF6a regulates the function of other lung structural cells such as fibroblasts or myofibroblasts. Further human studies are also needed to determine whether ORMDL3 regulates 197 ATF6 α in human ASM as it does in human bronchial epithelial cells⁴. 198

199

200 In addition to our studies of the ER demonstrating that ORMDL3 regulates ATF6a in mouse and human lung cells^{E3,E4}, previous studies have demonstrated that the ER resident protein 57 201 (ERp57) is upregulated in allergen challenged mouse and human lung epithelial cells^{E8}. Studies 202 203 of HDM challenged mice selectively deficient in ERp57 in epithelial cells demonstrated reduced airway inflammation (in particular neutrophils and lymphocytes), fibrosis, and AHR^{E9}. 204 Interestingly, in epithelial cells in vitro, ATF6a knockdown decreased HDM induced 205 upregulation of ERp57 and decreased apoptosis^{E8}. In contrast, ATF6a does not regulate levels of 206 apoptosis in ASM, suggesting that the ATF6a pathway to ERp57 differs in functional outcomes 207

| 208 | in epithelial cells and ASM. As ATF6 α is a transcription factor that regulates expression of at |
|-----|--|
| 209 | least 60 genes ^{E1} , further study is needed to determine which downstream pathway from ATF6 α |
| 210 | in ASM is important to ASM contractility. One candidate pathway downstream of ATF6 α is |
| 211 | sarco/endoplasmic reticulum Ca^{2+} ATPase 2b (SERCA2b) which like ORMDL3 and ATF6 α is |
| 212 | also localized in the ER. We have previously demonstrated that in vitro and in vivo, increased |
| 213 | expression of ORMDL3 leads to increased activation of ATF6 α and increased expression of |
| 214 | SERCA2b ^{E3,E4} . In addition, knockdown of ATF6 α reduces levels of SERCA2b expression ^{E3,E4} . |
| 215 | Thus, further study is needed to determine whether SERCA2b or other downstream pathways in |
| 216 | ASM mediate the effect of ATF6 α on ASM contractility. |
| 217 | |
| 218 | |
| 219 | |
| 220 | |
| 221 | |
| 222 | |
| 223 | |
| 224 | |
| 225 | |
| 226 | |
| 227 | |
| 228 | |
| 229 | |
| 230 | |

231 SUPPLEMENTARY FIGURE LEGENDS:

232

233 Supplementary Figure E1. No difference in airway inflammation in $ATF6a^{--}$ vs WT mice.

ATF6 $\alpha^{-/-}$ or WT mice (n = 8 mice/group) were challenged with HDM intranasally on day 0, 7, 14, 234 235 21. On day 24, levels of BAL cellular inflammation was quantitated, and lung tissues were 236 processed for immunohistology and image analysis. The number of Wright-Giemsa stained A, BAL eosinophils, **B**, BAL lymphocytes, **C**, BAL neutrophils, and **D**, BAL macrophages were 237 238 quantitated by light microscopy. E, The number of peribronchiole MBP⁺ eosinophils, F, CD4+ 239 lymphocytes, **G**, neutrophil elastase⁺ (NE⁺) neutrophils, and **H**, $F4/80^+$ macrophages per 240 bronchiole of 150-200µm internal diameter was quantitated by immunohistochemistry and image analysis. Levels of BAL I, IL-5, J, IL-13, and K, TGF^β1 were quantitated by ELISA. L, Levels 241 of eotaxin-1 were quantitated by ELISA in the supernatants of hASM stimulated with IL-13. *P 242 <0.05, *** *P* <0.001, and NS (not significant). 243

244

Supplementary Figure E2. Comparison of ASM contraction in non-siRNA treated hASM cells and control siRNA treated hASM cells in vitro.

Levels of smooth muscle contraction in non-siRNA treated hASM cells and control siRNA treated hASM cells were assessed at baseline (time 0 min), as well as 15 and 30 min after incubation with either **A**, methacholine, or **B**, histamine using an in vitro smooth muscle gel contraction assay. *P < 0.05, ***P < 0.001 and NS (not significant).

- 252
- 253

254 SUPPLEMENTARY REFERENCES

- E1. Adachi Y, Yamamoto K, Okada T, Yoshida H, Harada A, Mori K. ATF6 is a
 transcription factor specializing in the regulation of quality control proteins in the
 endoplasmic reticulum. Cell Struct Funct 2008; 33:75-89.
- 259
- E2. Doherty TA, Soroosh P, Khorram N, Fukuyama S, Rosenthal P, Cho JY, et al. The tumor
 necrosis factor family member LIGHT is a target for asthmatic airway remodeling. Nat
 Med. 2011;17:596-603.
- 263
- E3. Miller M, Rosenthal P, Beppu A, Mueller JL, Hoffman HM, Tam AB, et al. ORMDL3
 transgenic mice have increased airway remodeling and airway responsiveness
 characteristic of asthma. J Immunol 2014; 192:3475-87.
- 267
- E4. Miller M, Tam AB, Cho JY, Doherty TA, Pham A, Khorram N, et al. ORMDL3 is an
 inducible lung epithelial gene regulating metalloproteases, chemokines, OAS, and ATF6.
 Proc Natl Acad Sci U S A 2012; 109:16648-53.
- 271
- E5. Lauer M, Mukhopadhyay D, Fulop C, De la Motte C, Majors A, Hacall V. Primary
 Murine Airway Smooth Muscle Cells Exposed to Poly(I,C) or Tunicamycin Synthesize a
 Leukocyte-adhesive Hyaluronan Matrix. J Biol Chem 2009; 284:5299-312
- 275

| 276 | E6. | Xu W, Hong W, Shao Y, Ning Y, Cai Z, Li Q. Nogo-B regulates migration and contraction |
|-----|-----|---|
| 277 | | of airway smooth muscle cells by decreasing ARPC 2/3 and increasing MYL-9 |
| 278 | | expression. Respir Res. 2011; 12: 14. |
| 279 | | |
| 280 | E7. | Miller M, Beppu A, Rosenthal P, Pham A, Das S, Karta M, et al. Fstl1 promotes asthmatic |
| 281 | | airway remodeling by inducing oncostatin M. J Immunol 2015; 95:3546-56. |
| 282 | | |
| 283 | E8. | Hoffman SM, Tully JE, Nolin JD, Lahue KG, Goldman DH, Daphtary N, et al. |
| 284 | | Endoplasmic reticulum stress mediates house dust mite-induced airway epithelial |
| 285 | | apoptosis and fibrosis. Respir Res 2013; 14:141. |
| 286 | | |
| 287 | E9. | Hoffman SM, Chapman DG, Lahue KG, Cahoon JM, Rattu GK, Daphtary N, et al. |
| 288 | | Protein disulfide isomerase-endoplasmic reticulum resident protein 57 regulates allergen- |
| 289 | | induced airways inflammation, fibrosis, and hyperresponsiveness. J Allergy Clin |
| 290 | | Immunol 2016; 137:822-32. |
| 291 | | |
| 292 | | |



Е

н









F











